Chemo Brain Is Real. Survivors Deserve More Than Learning to Live With It.

October is Breast Cancer Awareness Month. For me, that inevitably means thinking about survivorship.

You may already be aware, but nearly six years ago, I was diagnosed with triple-negative breast cancer. I went through chemotherapy, surgery, and all of the uncertainty that comes with suddenly becoming a cancer patient. I am enormously grateful to be here.

But surviving cancer and returning to the person you were before cancer are not necessarily the same thing. And many cancer survivors will tell you that cognition is one of the things that changes.

One of the biggest changes I noticed after chemotherapy involved words. Sometimes a word I knew perfectly well—occasionally one I had used hundreds of times—would simply refuse to come when I reached for it. I knew what I wanted to say. I could almost feel the word sitting there. I just couldn't retrieve it as effortlessly as I once had. I also felt like I was speaking very slowly. I remember apologizing for it a few times and being met with confused faces—"I didn't think you were speaking slowly." So either it was my perception, or perhaps I used to talk way too fast! In any case, it felt different to me. It has improved with time.

We have become much better at helping people survive cancer. But what happens after treatment ends? What do we actually know about the cognitive changes some survivors experience, and more importantly, what are we doing to help them recover?

I'd like to talk about what we commonly call "chemo brain," or cancer-related cognitive impairment (CRCI). It isn't the same as dementia, nor is it generally a progressive neurodegenerative condition. But its effects can be persistent and frustrating.

And this is, after all, The Cognitive Clarity Project. So I'd like to explore this topic from three perspectives: as a cancer survivor, as a clinician, and as someone with advanced training in cognitive assessment.

When "Normal" Isn't Your Normal

People with CRCI describe problems with attention, memory, processing speed, executive function, multitasking, and language. In breast cancer survivors, chemotherapy and endocrine therapy have both been associated with cognitive changes, while fatigue, sleep disturbance, psychological distress, inflammation, and other biological factors may influence the experience as well.¹

There is also a persistent and fascinating problem in CRCI research: what survivors report doesn't always correlate neatly with what neuropsychological testing detects.¹

A standardized cognitive test and a cancer survivor may be asking two different questions. The test may be asking: How does this person's performance compare with what we expect? While the survivor may be asking: Does my brain work the way it did before cancer?

Those are not the same question.

A person can remain highly functional and still recognize that something that once felt automatic now requires effort. Like the example I gave above, there may be no dramatic failure that another person would actually notice. But the cancer survivor might. Sometimes it simply feels like thinking through resistance.

Like wading through mud.

The Question That Bothered Me

Years after my own treatment, my mother was diagnosed with brain cancer.

As I tried to understand her disease and treatment, I learned much more about chemotherapy and the blood-brain barrier (BBB). The BBB is a highly selective interface that regulates what moves from the circulatory system into the brain. I remember her oncologist telling me that chemotherapy options were limited because it is difficult to get them across the BBB.

Hold on. How is it that I ended up with effects in my brain from chemotherapy?

It sent me down a rabbit hole, looking back at my own chemotherapy experience.

One of the drugs I received was doxorubicin, also known in the cancer community as the "red devil." It's a particularly nasty form of chemotherapy, hence the name. Doxorubicin has limited ability to cross an intact blood-brain barrier.²

That seemed paradoxical.

If very little of the drug gets into the brain, how could so many women exposed to it be experiencing cognitive changes? The answer increasingly appears to be that a chemotherapy drug doesn't necessarily have to accumulate inside the brain to affect it.

The Brain Does Not Live in Isolation

The BBB is not a brick wall separating the brain from everything happening elsewhere in the body. It is a living biological interface.

Chemotherapy drugs like doxorubicin can produce substantial oxidative stress outside the central nervous system. That damage can trigger inflammation capable of affecting the brain as well as the cells that maintain the BBB.^2,3

Research has implicated several processes:

• Inflammatory cytokines: Small proteins that act as chemical messengers between cells, such as tumor necrosis factor-alpha (TNF-α).
• Activation of immune cells in the brain: Including cells called microglia and astrocytes.
• Oxidative stress: An imbalance between unstable molecules called free radicals and the body's ability to neutralize them with antioxidants.
• Changes in neurogenesis: The process of forming new nerve cells.
• Disruption in communication between nerve cells.
• Damage to mitochondria: The parts of our cells responsible for producing energy.^2,3

More recently, researchers have begun examining the BBB itself. A 2025 study found that doxorubicin disrupted mitochondrial energy production in the cells that help form this protective barrier, increased inflammation, and caused changes that may weaken the BBB's ability to protect the brain.⁴

Mitochondria are attracting particular attention.

A 2026 review suggested that damage to mitochondria may help explain several of the ways chemotherapy affects the brain. When mitochondria don't function properly, they may contribute to inflammation, BBB damage, and disrupted communication between brain cells, potentially leading to cognitive problems.⁵

Much of this evidence remains preclinical. We should be careful not to take something demonstrated in a cell or animal and declare that we have discovered exactly what happened inside an individual survivor's brain.

But the old explanation of "chemotherapy makes you a little foggy" is increasingly inadequate. Real biological changes appear to be happening here.

And Then There Are Hormones

For younger women with breast cancer, there is another layer that can be remarkably difficult to untangle.

Chemotherapy can abruptly disrupt ovarian function and induce premature menopause. I read an article recently in which a woman was trying to explain how her sudden menopause was very different from women who naturally go through this change, slowly and progressively. For women experiencing what is sometimes called "chemopause," it can be fast and intense.

Estrogen has important effects throughout the brain, and menopause itself is associated with increased cognitive complaints. Endocrine therapies that alter estrogen signaling have also been associated with changes in verbal memory, processing speed, and other cognitive domains, although results across studies are not completely consistent.^3,6

For more on how menopause itself affects cognition, see Why Your Brain Feels Different During Menopause.

So when a younger woman experiences cognitive changes after breast-cancer treatment, what exactly are we measuring?

• Direct or indirect effects of chemotherapy?
• Neuroinflammation?
• Mitochondrial injury?
• Premature menopause?
• Sleep disruption?
• Fatigue?
• Metabolic changes?
• Some combination of all of them?

"Chemo brain" may ultimately prove to be an umbrella term covering several overlapping biological processes rather than one disorder with one mechanism.

That matters when we start asking the question survivors actually care about.

Can we treat it?

What Can We Do About It?

This is where I find the current state of CRCI research both encouraging and frustrating.

There are interventions that can help.

Exercise has accumulated some of the strongest evidence. A 2026 network meta-analysis encompassing 27 studies and 2,809 participants found benefits not only in self-reported cognition but also in objectively measured executive function, working memory, and processing speed. No single type of exercise was superior across every cognitive domain.⁷

Cognitive rehabilitation and cognitive training have also demonstrated benefits in some studies. Current research includes therapist-guided rehabilitation, computerized cognitive training, compensatory strategies, mindfulness-based interventions, and multimodal programs. The evidence remains heterogeneous, particularly when subjective improvement is compared with objective cognitive testing.⁸

Those interventions have value, but I also think survivors are entitled to say that they are not enough.

Someone who has already completed months of cancer treatment, returned to work, resumed caring for a family, and rebuilt a life may not be particularly excited to hear that the solution to a brain that requires more effort is to exercise and add cognitive homework to the end of the day. And I don't think most people truly appreciate just how exhausted you can feel, sometimes for years, following chemotherapy.

It's worth looking at the deeper question: What happened biologically, and can we repair it?

What About Medication?

Researchers have tried, largely by looking at medications we already have and considering whether they might help. Two types of drugs have received particular attention: acetylcholinesterase inhibitors, which are used to treat symptoms of dementia, and stimulants, commonly prescribed for attention-deficit disorders.

Donepezil, a medication used to treat symptoms of Alzheimer's disease, was tested in a large randomized phase III trial involving 276 breast-cancer survivors who reported cognitive problems one to five years after chemotherapy.

It didn't work.

After 24 weeks, donepezil produced no significant improvement over placebo in memory, attention, executive function, verbal fluency, processing speed, or self-reported cognitive function.⁹

The second drug was more interesting. In August 2026, researchers reported results from a small randomized, placebo-controlled pilot study of methylphenidate in women with persistent cognitive dysfunction following breast-cancer treatment. Participants receiving methylphenidate reported greater improvement in perceived cognitive impairment than those receiving placebo. Objective neuropsychological testing showed no significant difference, and the study included only 20 women, so this is nowhere near enough evidence to establish methylphenidate as a treatment for CRCI.

But it is enough to justify a larger trial.¹⁰ And given what we know about the disconnect between cognitive testing and the symptoms patients actually experience, perhaps improvement in how someone feels and functions deserves more weight, even when test scores don't show a measurable change.

Some Unexpected Leads

Researchers are also beginning to investigate biological pathways that would have sounded fairly unconventional not long ago.

One is the gut microbiome.

In a randomized, double-blind trial of 159 women with stage I–III breast cancer receiving chemotherapy, probiotic supplementation reduced the occurrence of CRCI compared with placebo. Researchers also identified changes in gut microbial composition and circulating metabolites and subsequently demonstrated effects involving synaptic injury, oxidative stress, and glial activation in an animal model.¹¹

This was a prevention study conducted during chemotherapy, not a treatment for someone with persistent CRCI years later. Still, it raises some fascinating questions:

• Can changes in the gut influence how the brain responds to chemotherapy?
• Could probiotics also help people who are experiencing cognitive problems years after treatment?
• Are there particular types of bacteria that offer greater benefits than others?

A study published in January 2026 made the gut-brain connection even more interesting. Researchers gave mice the same chemotherapy combination I received: doxorubicin, cyclophosphamide, and paclitaxel (AC-T). They found changes in the gut microbiome, intestinal inflammation, and altered activity of genes involved in communication between brain cells, neurogenesis, and plasticity. The mice also showed difficulties with social recognition memory, i.e. recognizing other mice.¹²

Of course, these were mice, not people, and the study doesn't prove that changes in the gut caused the cognitive problems. But it raises an important question: Could some of the cognitive effects of chemotherapy be influenced by changes occurring outside the brain? And if so, could treating those changes help?

I want to caution against starting a probiotic supplement based on these findings alone, particularly during active cancer treatment, without discussing it with a healthcare provider. Probiotics aren't all the same. Even different strains of the same bacterial species can have different effects, and results from one formulation don't necessarily apply to another.

We still have a lot to learn about which bacteria might be helpful, who might benefit, and whether there are risks for certain patients.

Another avenue being evaluated is melatonin.

A very small randomized trial of 36 women receiving adjuvant breast-cancer chemotherapy tested 20 mg of melatonin around the first chemotherapy cycle. Investigators reported improvements in executive function, episodic memory, recognition, and verbal fluency compared with placebo.¹³

Again, this was essentially a neuroprotection study during treatment—not evidence that taking melatonin years later reverses CRCI.

And just this month, researchers at UCLA reported another interesting finding.

In a small study of 18 breast cancer survivors experiencing persistent cognitive difficulties, researchers tested oxaloacetate, a substance naturally involved in how our cells produce energy. After eight weeks, all 16 women who completed the study reported improvements in their cognitive symptoms. Testing also showed improvements in processing speed and executive function, and participants reported less fatigue.¹⁴

The findings are encouraging, particularly because the researchers were studying women who were already experiencing cognitive problems after cancer treatment. But there is an important limitation: the study did not include a placebo group. We cannot yet say whether oxaloacetate was responsible for the improvements.

A larger, placebo-controlled trial is being planned.

What makes this study especially interesting is that researchers are investigating a possible biological contributor to CRCI—changes in how the brain produces and uses energy—rather than focusing solely on ways to compensate for cognitive difficulties.

There is an important distinction between preventing cognitive injury during chemotherapy, improving symptoms after treatment, and actually reversing the biological changes that may underlie persistent impairment. These are different research questions, and we need to be careful not to confuse them.

But I'm encouraged that researchers are asking these questions at all.

We Can Ask for More Than Survival

There is growing recognition that we need to do a better job of evaluating these changes. In 2026, the American Society of Clinical Oncology published a review emphasizing the importance of listening to patients' cognitive complaints, using standardized testing when appropriate, and providing individualized support.¹⁵

These are important steps, but recognizing cognitive changes and helping people manage them are only part of the challenge. We also need to understand how to treat them.

We need more research into why some people experience persistent cognitive problems while others don't. We need to understand the roles of inflammation, hormones, mitochondrial dysfunction, and the other biological changes that may be involved. And we need more clinical trials focused on helping people who are already living with these symptoms, not just preventing them during treatment.

I am profoundly grateful for chemotherapy. Having been diagnosed with an aggressive form of breast cancer, I'm certain I would not still be here today without it.

But I also know that surviving cancer doesn't mean everything goes back to the way it was before. I hear similar experiences from women in the survivorship groups I'm part of, and I know how frustrating it can be to recognize a change in yourself that isn't always obvious to someone else.

I don't regret the treatment that helped give me these six years. And I hope that the women who face this diagnosis in the years ahead will have even better treatments, with fewer lasting effects.

For those of us already living with the consequences, I hope medicine continues looking for ways to help us recover, rather than simply teaching us to adjust.

Gratitude for surviving cancer should never mean we have to stop asking for better.

References

1. Oliva G, Giustiniani A, Danesin L, Burgio F, Arcara G, Conte P. Cognitive impairment following breast cancer treatments: an umbrella review. Oncologist. 2024;29(7):e848-e863. doi:10.1093/oncolo/oyae090
2. Du J, Zhang A, Li J, et al. Doxorubicin-induced cognitive impairment: the mechanistic insights. Front Oncol. 2021;11:673340. doi:10.3389/fonc.2021.673340
3. Fleming B, Edison P, Kenny L. Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management. BMJ. 2023;380:e071726. doi:10.1136/bmj-2022-071726
4. Patel C, Glytsou C, Jang MH, Cole PD. The effects of doxorubicin on blood-brain barrier integrity in hCMEC/D3. Neurotoxicology. 2025;111:103355. doi:10.1016/j.neuro.2025.103355
5. Chen J, Chu X, Wu Y, et al. Mechanistic insights and therapeutic interventions of mitochondrial quality control in chemotherapy-related cognitive impairment. Neoplasia. 2026;74:101291. doi:10.1016/j.neo.2026.101291
6. Van Dyk K, Ganz PA. Cancer-related cognitive impairment in patients with a history of breast cancer. JAMA. 2021;326(17):1736-1737. doi:10.1001/jama.2021.13309
7. Cheng W, Fang J, Li H, et al. Effects of exercise-based interventions on cancer-related cognitive impairment: a systematic review and network meta-analysis. Arch Phys Med Rehabil. Published online August 16, 2026. doi:10.1016/j.apmr.2026.07.032
8. Andreis F, Deori C, Giubileo V, et al. Cancer-related cognitive impairment in breast cancer: current state of knowledge, mechanisms, diagnosis, prevention and treatment. Cancers (Basel). 2026;18(12):1974. doi:10.3390/cancers18121974
9. Rapp SR, Dressler EV, Brown WM, et al. Phase III randomized, placebo-controlled clinical trial of donepezil for treatment of cognitive impairment in breast cancer survivors after adjuvant chemotherapy (WF-97116). J Clin Oncol. 2024;42(21):2546-2557. doi:10.1200/JCO.23.01100
10. Boivin J, Dagnault A, Dogba MJ, et al. Positive effect of methylphenidate for cancer-related cognitive impairment: a pilot randomized trial. J Pain Symptom Manage. Published online August 22, 2026. doi:10.1016/j.jpainsymman.2026.08.010
11. Juan Z, Chen J, Ding B, et al. Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial. Eur J Cancer. 2022;161:10-22. doi:10.1016/j.ejca.2021.11.006
12. Cronin B, Kandel S, McElroy T, et al. Changes in gut, microbiome, and cognition after doxorubicin, cyclophosphamide, and paclitaxel chemotherapy treatment. Sci Rep. 2026;16:3820. doi:10.1038/s41598-025-33903-w
13. Palmer ACS, Zortea M, Souza A, et al. Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: a randomized, double-blind, placebo-controlled trial. PLoS One. 2020;15(4):e0231379. doi:10.1371/journal.pone.0231379
14. Results from a phase II single-arm trial evaluating the safety and efficacy of anhydrous enol-oxaloacetate on improving cognitive complaints in breast cancer survivors. JCO Oncol Adv. 2026. doi:10.1200/OA-26-00063
15. Assessment and management of cancer-related cognitive impairment. ASCO Educational Book. 2026. doi:10.1200/EDBK-26-517676